Objective: To explore the feasibility of cardiopulmonary exercise test (CPET) in leukemia patients after chemotherapy.
Methods: Leukemia patients with histologically confirmed hematologic malignancies were reviewed. We evaluated for CPET, between receiving chemotherapy and undergoing stem cell transplantation after 2 weeks. We recorded exercise testing and physiologic parameters during CPET between January 2013 to May 2015. All patients were subjected to symptoms limited to exercise testing, according to the Modified Bruce Protocol. We considered that if respiratory exchange ratio achieved was over 1.10, participants had successfully completed CPET. We dichotomized all participants into two groups (normal group, normal range of resting heart rate; higher group, over 100 per minute of heart rate).
Results: 30 patients were finally enrolled. All participants had no adverse effects during the exercise test. Mean peak double product was 26,998.60 mmHg·beats/min (range, 15,481-41,004), and mean peak oxygen consumption (VO peak) was 22.52±4.56 mL/kg/min. Significant differences were observed in the normal group with VO peak (mean, 24.21 mL/kg/min; p=0.027) and number of prior intensive chemotherapy, compared to the higher group (mean, 1.95; p=0.006).
Conclusion: Our results indicate that CPET in leukemia patients before stem cell transplantation was very safe, and is an efficient method to screen for patients with poor cardiac functions. As CPET presents the parameters which reveal the cardiopulmonary functions, including VO peak, double product and exercise capacity, this exercise test would help to predict the physical performance or general condition of the leukemia patients.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5532352 | PMC |
http://dx.doi.org/10.5535/arm.2017.41.3.456 | DOI Listing |
Arch Argent Pediatr
January 2025
Infectious Diseases Service, Hospital de Niños Sor María Ludovica, La Plata, Argentina.
Mucormycosis is an opportunistic fungal infection with high mortality, especially in immunocompromised patients. This article emphasizes the importance of early diagnosis and aggressive treatment. We describe the case of a child with leukemia treated with corticosteroids, vincristine, and daunorubicin, who developed rhino-orbital mucormycosis.
View Article and Find Full Text PDFPediatr Blood Cancer
January 2025
University Medical Center Utrecht, Utrecht, The Netherlands.
Background: A pediatric cancer diagnosis is overwhelming and stressful for the whole family. Patient-centered communication during the diagnostic conversation can support medical and psychosocial adaptation to the disease. Treatment of pediatric leukemia has become increasingly complex and requires a specific skillset from clinicians in effectively conveying information to families.
View Article and Find Full Text PDFPediatr Blood Cancer
January 2025
Hong Kong Children's Hospital, Kowloon, Hong Kong SAR, China.
Paediatric relapse/refractory T-cell acute lymphoblastic leukaemia (T-ALL) is notoriously difficult to treat. This group of heavily pre-treated patients needs effective agents that can rapidly control the disease while not having significant toxicity. Homoharringtonine (HHT) has been widely used in children with acute myeloid leukaemia, but there is little information on T-ALL.
View Article and Find Full Text PDFEJHaem
February 2025
Service d'Hématologie Clinique et de Thérapie Cellulaire CHU de Bordeaux Pessac Nouvelle-Aquitaine France.
Introduction: Adults with relapsed or refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukaemia (R/R Ph+ BCP-ALL) have a dismal outcome. Blinatumomab as a single agent has shown activity in R/R Ph- BCP-ALL, and second or third-generation tyrosine kinase inhibitors (TKIs) can produce high remission rates in Ph+ leukaemias. We aimed to assess the activity of blinatumomab and TKI in combination with intensive chemotherapy in the relapsed or refractory setting.
View Article and Find Full Text PDFNiger Med J
January 2025
Department of Pathology (Hematology section), Indira Gandhi Institute of Medical Sciences, Patna, India.
Hydroxyurea (HU) is frequently used in the treatment of various myeloproliferative neoplasms (MPN) where it reduces cell proliferation by impairing DNA synthesis leading to decreased hematopoiesis. Herein we report a case of a 65-year-old female who was diagnosed with Chronic myeloid leukemia and developed severe hemolytic anemia requiring multiple packed red blood cell (RBC) transfusions while being treated with hydroxyurea. The haemolysis persisted until discontinuation of the drug.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!